Enjoy complimentary customisation on priority with our Enterprise License!
The liver cancer drugs market is estimated to grow by USD 3.28 billion at a CAGR of 10.03% between 2024 and 2028. Liver cancer is a significant health concern with increasing incidence rates worldwide. Early detection is crucial for effective treatment, and advancements in diagnostic methods have played a pivotal role in improving outcomes. Technologies such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and ultrasounds have become more accurate in identifying liver lesions. Moreover, the development of non-invasive diagnostic tools like elastography and serum biomarker tests has further enhanced the diagnostic process. The favorable reimbursement scenario for liver cancer treatments in various regions, including Europe and the United States, provides incentives for patients to undergo early diagnosis and treatment. These factors collectively contribute to the growth of the global liver cancer diagnostic market.
For More Highlights About this Report, Request Free Sample
Liver cancer, also known as hepatic cancer, is a malignant growth in the liver that can be primary or metastatic. Primary liver cancer includes hepatocellular carcinoma (HCC), hepatoblastoma, and intrahepatic carcinoma. The disease is often linked to chronic hepatitis infections, particularly Hepatitis B and C, as well as liver cirrhosis and lifestyle practices. According to public health authorities, liver cancer is the sixth most common cancer and the third leading cause of cancer deaths worldwide. The 5-year survival rate for liver cancer is relatively low, with less than 20% of patients surviving beyond five years. The market is witnessing significant growth due to the increasing number of cases and the need for effective treatments. Immunotherapy and novel drugs are at the forefront of drug development, offering new hope for patients. Medications such as sorafenib, lenvatinib, and regorafenib are currently used to treat advanced HCC. Genome-targeted therapy is also a promising area of research. Public awareness and early diagnosis are crucial for improving the prognosis of liver cancer. The geriatric population and men are more susceptible to liver cancer, while women have a lower incidence rate. The intrahepatic bile duct is another area of focus in liver cancer research. The drug development pipeline is robust, with several promising candidates in various stages of clinical trials. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing incidence of liver cancer is notably driving market growth. Liver cancer is a significant health concern worldwide, with hepatitis B and C infections and cirrhosis being major contributing factors. In the United States, approximately 31,000 people are diagnosed annually, with over half of these cases linked to hepatitis C and 15% to hepatitis B. According to ASCO, the American Society of Clinical Oncology, an estimated 41,210 adults (27,980 men and 13,230 women) in the US will be diagnosed with primary liver cancer in 2023.
Furthermore, unsafe injection practices, a growing geriatric population, and lifestyle factors such as non-alcoholic steatohepatitis (NASH) further increase the risk of liver cancer. The drug development pipeline includes novel drugs like genome-targeted therapy and targeted therapy, such as sorafenib, which has a response rate of 20-30% for advanced HCC (hepatocellular carcinoma). Public awareness campaigns and improvements in vaccination programs are essential to prevent the spread of hepatitis and reduce the incidence of liver cancer. Intrahepatic bile ducts can also be affected, leading to cholangiocarcinoma. Chemotherapy remains a common treatment option, although its effectiveness varies depending on the stage of the disease. Thus, such factors are driving the growth of the market during the forecast period.
Increasing use of monoclonal antibodies is the key trend in the market. Monoclonal antibodies are gaining significant attention in the treatment of liver cancer due to their high sensitivity and specificity, which reduces the risk of adverse side effects. The primary challenge in developing effective liver cancer drugs is the limited understanding of tumor-specific targets. Research is underway to create high-stability and high-affinity antibodies and fragments that can target antigens unique to liver cancer.
Furthermore, the aging population and lifestyle practices, such as non-alcoholic steatohepatitis, are contributing factors to the rising incidence of liver cancer in men and women. Vaccination programs and public awareness campaigns are essential to prevent unsafe injection practices and promote early detection. The drug development pipeline includes genome-targeted therapies, such as HCC-specific targeted therapy and chemotherapy, with varying response rates. Novel drugs, such as intrahepatic bile duct-targeted therapy, are also being explored to improve treatment outcomes. Thus, such trends will shape the growth of the market during the forecast period.
The only curative option is surgical resection and transplantation is the major challenge affecting the market's growth. Liver cancer treatment options depend on the disease's stage and liver function. Currently, there are no disease-modifying drugs available in the market or in the drug development pipeline to potentially cure liver cancer. Surgical resection and liver transplantation are the only curative modalities for liver cancer. However, global consensus on surgical treatment as the recommended option is lacking due to varying healthcare systems in different regions.
Furthermore, surgical resection is only suitable for candidates who meet the prerequisites for surgery. Despite its curative potential, liver resection is associated with a high recurrence rate of tumors. In the meantime, efforts are being made to develop novel drugs, including genome-targeted therapy and targeted therapy, for liver cancer treatment. Public awareness campaigns are crucial to prevent unsafe injection practices and promote lifestyle modifications, such as controlling non-alcoholic steatohepatitis, to reduce the risk of liver cancer in men and women. The aging population is particularly vulnerable to liver cancer, making it essential to prioritize research and development in this area. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and understanding its mechanisms and developing effective treatments remains a significant challenge. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Bayer AG - The company offers drugs, treatment, and diagnoses for liver cancer.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the Immunotherapy segment will be significant during the forecast period. Liver cancer, a formidable health concern, continues to pose a significant challenge to public health authorities worldwide. According to Elsevier, liver cancer is the sixth most common cancer and the third leading cause of cancer-related deaths. The primary types of liver cancer include hepatocellular carcinoma, hepatoblastoma, and intrahepatic carcinoma.
Get a glance at the market share of various regions Download the PDF Sample
The Immunotherapy segment showed a gradual increase in the market share of USD 2.56 billion in 2018. Diagnosis often comes late due to non-specific symptoms, leading to poor 5-year survival rates. Chronic hepatitis infections, particularly from Hepatitis B and C, are leading risk factors. Malignant cells develop in liver tissues, disrupting the hepatic architecture and leading to complications such as cirrhosis and death. Medications like sorafenib, lenvatinib, regorafenib, and ramucirumab offer immunotherapy and chemotherapeutic options. Treatment modalities include hepatectomy, liver transplantation, ablation, and radiation therapy. Animal models are used to study liver cancer, shedding light on the role of excess fat production, body mass, serum enzyme levels, and viral hepatitis treatment in disease progression. Screening criteria are essential to improve early detection and reduce mortality rates.
For more insights on the market share of various regions Download PDF Sample now!
Europe is estimated to contribute 33% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Liver cancer, a malignant growth in the liver, is a major public health concern with high mortality rates. According to Elsevier, primary liver cancers include hepatocellular carcinoma (HCC), hepatoblastoma, and intrahepatic cholangiocarcinoma. Diagnosis is often challenging due to nonspecific symptoms and lack of effective screening criteria. Chronic hepatitis infections, particularly Hepatitis B and C, are significant risk factors. Hepatocellular carcinoma accounts for over 90% of liver cancer cases. The 5-year survival rate for liver cancer is low, with only 18% of patients surviving beyond five years. Treatment options include medications, such as immunotherapy and chemotherapeutic medications like Sorafenib, Lenvatinib, Regorafenib, and Ramucirumab. Hepatectomy, liver transplantation, ablation, and radiation therapy are also used. Malignant cells disrupt liver tissues, leading to deaths from liver failure, cirrhosis, and metastasis. Risk factors include excess fat production, body mass index, serum enzyme levels, hepatic architecture, and viral hepatitis treatment. Animal models are used to study liver cancer, providing insights into disease progression and potential treatments. Chronic hepatitis infections, liver cirrhosis, and type 2 diabetes contribute to liver cancer development. The World Health Organization recommends regular screening for high-risk individuals, including those with chronic hepatitis, cirrhosis, and obesity. Early diagnosis and effective treatment can improve outcomes and save lives.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
Oncology Drugs Market: Oncology Drugs Market - North America, Europe, EMEA, APAC : US, Canada, China, Germany, UK - Forecast
Non-small Cell Lung Cancer Drugs Market: Non-small Cell Lung Cancer Drugs Market by Type, Product, and Geography - Forecast and Analysis
Liver cancer, also known as hepatic cancer, is a malignant growth in the liver that can be primary or metastatic. Primary liver cancer includes hepatocellular carcinoma (HCC), hepatoblastoma, and intrahepatic carcinoma. Public health authorities have reported a significant increase in liver cancer cases, with HCC being the most common type. The 5-year survival rate for liver cancer is relatively low, making the development of effective treatments a priority. Diagnosis of liver cancer involves various methods such as imaging techniques, liver function tests, and biopsy. Chronic hepatitis infections, particularly Hepatitis B and C, are significant risk factors for liver cancer.
Furthermore, other factors include liver cirrhosis, obesity, and excess fat production associated with Type 2 diabetes. Medications like Sorafenib, Lenvatinib, Regorafenib, and Ramucirumab are used to treat liver cancer. Immunotherapy and chemotherapeutic medications are also used. Hepatectomy, liver transplantation, ablation, and radiation therapy are surgical and non-surgical treatment options. Researchers are exploring new treatments using animal models to understand the behavior of malignant cells in liver tissues. Elsevier, a leading scientific publisher, has published numerous studies on liver cancer, including the role of hepatic architecture, serum enzyme levels, and viral hepatitis treatment in liver cancer development. Screening criteria for liver cancer include regular monitoring of serum enzyme levels, body mass index, and viral hepatitis status. Early detection and treatment can significantly improve the 5-year survival rate.
Market Scope |
|
Report Coverage |
Details |
Page number |
142 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.03% |
Market growth 2024-2028 |
USD 3.28 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
8.88 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
Europe at 33% |
Key countries |
US, Germany, China, Canada, and UK |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Q BioMed Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.